Metabolic Effects of n-3 PUFA as Phospholipids Are Superior to Triglycerides in Mice Fed a High-Fat Diet: Possible Role of Endocannabinoids
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: n-3 polyunsaturated fatty acids, namely docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), reduce the risk of cardiovascular disease and can ameliorate many of obesity-associated disorders. We hypothesised that the latter effect will be more pronounced when DHA/EPA is supplemented as phospholipids rather than as triglycerides. METHODOLOGY/PRINCIPAL FINDINGS: In a 'prevention study', C57BL/6J mice were fed for 9 weeks on either a corn oil-based high-fat obesogenic diet (cHF; lipids ∼35% wt/wt), or cHF-based diets in which corn oil was partially replaced by DHA/EPA, admixed either as phospholipids or triglycerides from marine fish. The reversal of obesity was studied in mice subjected to the preceding cHF-feeding for 4 months. DHA/EPA administered as phospholipids prevented glucose intolerance and tended to reduce obesity better than triglycerides. Lipemia and hepatosteatosis were suppressed more in response to dietary phospholipids, in correlation with better bioavailability of DHA and EPA, and a higher DHA accumulation in the liver, white adipose tissue (WAT), and muscle phospholipids. In dietary obese mice, both DHA/EPA concentrates prevented a further weight gain, reduced plasma lipid levels to a similar extent, and tended to improve glucose tolerance. Importantly, only the phospholipid form reduced plasma insulin and adipocyte hypertrophy, while being more effective in reducing hepatic steatosis and low-grade inflammation of WAT. These beneficial effects were correlated with changes of endocannabinoid metabolome in WAT, where phospholipids reduced 2-arachidonoylglycerol, and were more effective in increasing anti-inflammatory lipids such as N-docosahexaenoylethanolamine. CONCLUSIONS/SIGNIFICANCE: Compared with triglycerides, dietary DHA/EPA administered as phospholipids are superior in preserving a healthy metabolic profile under obesogenic conditions, possibly reflecting better bioavalability and improved modulation of the endocannabinoid system activity in WAT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Rossmeisl and colleagues (2012), observed favourable metabolic changes when omega-3 PUFAs were available as phospholipids compared with TAGs, possibly due to different bio-availabilities [169].”
From Omega-3 Fatty Acids and Skeletal Muscle Health (2015) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“components of the metabolic syndrome [1], are a major public health problem.”
Backgroundn−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525 · cited 1×
“It is also likely that the more potent reductions of AA in the phospholipid and diacylglycerol pools associated with (i) AA replacement in membrane phospholipids by LC n-3 PUFA (for reviews, see [45,46]), and (ii) lower dietary content of LA, which is the precursor of AA, contribute to the superior anti-inflammatory e…”
BackgroundOh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162 · cited 1×
“In agreement with the previous observation in both humans [41] and mice [42], saturable incorporation of DHA into total plasma lipids was observed, while a linear relationship between dietary concentration of EPA and its plasma level was found, which contributed to a relatively high bioavailability of EPA from the pho…”
Backgroundn–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
Blasbalg, T. L., Hibbeln, J. R., Ramsden, C. E., Majchrzak, S. F., & Rawlings, R. R. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.006643 · Cited by 881 · cited 1×
“In fact, the increase in obesity prevalence in the United States during the 20th century could be in part due to the elevated consumption of LA, the precursor of AA, and hence also the precursor of the AA-derived endocannabinoids [53,54].”
BackgroundFish Oil Prevents Insulin Resistance Induced by High-Fat Feeding in Rats
Storlien, L. H., Kraegen, E. W., Chisholm, D. J., Ford, G. L., Bruce, D. G., & Pascoe, W. S. (1987) · Science · doi:10.1126/science.3303333 · Cited by 650 · cited 1×
“However, in spite of the fact that LC n-3 PUFA could help to reduce obesity in humans [16,17] and prevent insulin resistance in rodents [8,18], they do not reverse insulin resistance in diabetic patients [19].”
BackgroundIdentification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver
Chakravarthy, M. V., Lodhi, I. J., Yin, L., Malapaka, R. R. V., Xu, H. E., Turk, J., & Semenkovich, C. F. (2009) · Cell · doi:10.1016/j.cell.2009.05.036 · Cited by 533
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Blüher, M., Engeli, S., Klöting, N., Berndt, J., Fasshauer, M., Bátkai, S., Pacher, P., Schön, M. R., Jordan, J., & Stumvoll, M. (2006) · Diabetes · doi:10.2337/db06-0812 · Cited by 530 · cited 4×
“Also the activity of endocannabinoid system [23], which is dysregulated in obesity [24], is modulated in response to LC n-3 PUFA intake.”
BackgroundResultInfluentialCardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 511 · cited 1×
“In this respect, dietary intake of marine fish oils, namely long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) such as docosahexaenoic acid (DHA; 22:6n-3) and eicosapentaenoic acid (EPA; 20:5n-3), have been shown to exert profound hypolipidemic effects [2,3], reducing systemic inflammation [4,5] as well as low-g…”
BackgroundOsei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.-I., Bátkai, S., Marsicano, G., Lutz, B., Buettner, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34827 · Cited by 458 · cited 1×
“The pathophysiological role of the endocannabinoid system in the development of adipose tissue inflammation [47] or hepatic steatosis [48,49] is well described, and anti-inflammatory effects of adipocyte-derived EPEA or DHEA have recently been suggested [50,51].”
BackgroundThe sor Gene of HIV-1 Is Required for Efficient Virus Transmission in Vitro
Fisher, A. G., Ensoli, B., Ivanoff, L., Chamberlain, M., Petteway, S., Ratner, L., Gallo, R. C., & Wong-Staal, F. (1987) · Science · doi:10.1126/science.3497453 · Cited by 357
Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet
Flachs, P., Mohamed-Ali, V., Horakova, O., Rossmeisl, M., Hosseinzadeh-Attar, M. J., Hensler, M., Ruzickova, J., & Kopecky, J. (2006) · Diabetologia · doi:10.1007/s00125-005-0053-y · Cited by 357
Self-citationn-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review
Nettleton, J. A., & Katz, R. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.11.029 · Cited by 339
Ruzickova, J., Rossmeisl, M., Prazak, T., Flachs, P., Sponarova, J., Vecka, M., Tvrzicka, E., Bryhn, M., & Kopecky, J. (2004) · Lipids · doi:10.1007/s11745-004-1345-9 · Cited by 327 · cited 1×
“Accordingly, we have observed before in mice that supplementation of a high-fat diet by LC n-3 PUFA, under very similar conditions as used in the ‘prevention study’ here, reduced body fat depots when LA formed 53% of dietary lipids, but did not affect adiposity when the LA content represented 15% of dietary fat [55].”
MethodSelf-citationTodoric, J., Löffler, M., Huber, J., Bilban, M., Reimers, M., Kadl, A., Zeyda, M., Waldhäusl, W., & Stulnig, T. M. (2006) · Diabetologia · doi:10.1007/s00125-006-0300-x · Cited by 310
Ulven, S. M., Kirkhus, B., Lamglait, A., Basu, S., Elind, E., Haider, T., Berge, K., Vik, H., & Pedersen, J. I. (2011) · Lipids · doi:10.1007/s11745-010-3490-4 · Cited by 303 · cited 1×
“In line with previous studies [30–34], our results document better bioavailability of both DHA and EPA when supplemented as dietary phospholipids and this effect can largely be attributed to a marked improvement in EPA bioavailability (see also ref.”
ResultFish oil and glycemic control in diabetes. A meta-analysis.
Friedberg, C. E., Janssen, M. J. F. M., Heine, R. J., & Grobbee, D. E. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.494 · Cited by 303 · cited 1×
“However, in spite of the fact that LC n-3 PUFA could help to reduce obesity in humans [16,17] and prevent insulin resistance in rodents [8,18], they do not reverse insulin resistance in diabetic patients [19].”
BackgroundMori, T. A., Bao, D. Q., Burke, V., Puddey, I. B., Watts, G. F., & Beilin, L. J. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/70.5.817 · Cited by 296 · cited 1×
“However, in spite of the fact that LC n-3 PUFA could help to reduce obesity in humans [16,17] and prevent insulin resistance in rodents [8,18], they do not reverse insulin resistance in diabetic patients [19].”
BackgroundSchuchardt, J., Schneider, I., Meyer, H., Neubronner, J., von Schacky, C., & Hahn, A. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-145 · Cited by 291 · cited 1×
“In line with previous data on krill oil [11,25,26,35], our results support the notion that the endocannabinoid system is involved in the mechanism of action of LC n-3 PUFA.”
ResultFlachs, P., Rossmeisl, M., Bryhn, M., & Kopecky, J. (2009) · Clinical Science · doi:10.1042/cs20070456 · Cited by 286 · cited 1×
“It is also likely that the more potent reductions of AA in the phospholipid and diacylglycerol pools associated with (i) AA replacement in membrane phospholipids by LC n-3 PUFA (for reviews, see [45,46]), and (ii) lower dietary content of LA, which is the precursor of AA, contribute to the superior anti-inflammatory e…”
BackgroundSelf-citationRegulation of adipocyte differentiation and function by polyunsaturated fatty acids
Madsen, L., Petersen, R. K., & Kristiansen, K. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.03.001 · Cited by 281 · cited 3×
“These data are consistent with the notion that cell membrane phospholipids represent an important reservoir of DHA and EPA and their processing into lipid signalling molecules [9,20,22], and they suggest that the difference in the effectiveness of the treatments is largely explained by differential accumulation of DHA…”
BackgroundResultNeschen, S., Morino, K., Rossbacher, J. C., Pongratz, R. L., Cline, G. W., Sono, S., Gillum, M., & Shulman, G. I. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-0985 · Cited by 275
Dietary Linoleic Acid Elevates Endogenous 2‐AG and Anandamide and Induces Obesity
Alvheim, A. R., Malde, M. K., Osei‐Hyiaman, D., Hong, Y. H., Pawlosky, R. J., Madsen, L., Kristiansen, K., Frøyland, L., & Hibbeln, J. R. (2012) · Obesity · doi:10.1038/oby.2012.38 · Cited by 249
Batetta, B., Griinari, M., Carta, G., Murru, E., Ligresti, A., Cordeddu, L., Giordano, E., Sanna, F., Bisogno, T., Uda, S., et al. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.104844 · Cited by 244 · cited 4×
“In contrast to another report [25], the levels of AEA in WAT were relatively low and were further reduced by LC n-3 PUFA in the diet.”
BackgroundResultInfluentialLi, Y., Choi, M., Cavey, G., Daugherty, J., Suino, K., Kovach, A., Bingham, N. C., Kliewer, S. A., & Xu, H. E. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.002 · Cited by 205 · cited 1×
“It is likely that supplementation of LC n-3 PUFA as phospholipids exerts stronger biological effects compared with the triglyceride form because (i) various phospholipid species can also act as ligands for nuclear receptors, such as PPAR-a [28], steroidogenic factor-1, and liver receptor homolog-1 [29], which are invo…”
BackgroundMaki, K. C., Reeves, M. S., Farmer, M., Griinari, M., Berge, K., Vik, H., Hubacher, R., & Rains, T. M. (2009) · Nutrition Research · doi:10.1016/j.nutres.2009.09.004 · Cited by 192 · cited 2×
“In line with previous studies [30–34], our results document better bioavailability of both DHA and EPA when supplemented as dietary phospholipids and this effect can largely be attributed to a marked improvement in EPA bioavailability (see also ref.”
ResultNovel ? ? 3-derived local mediators in anti-inflammation and resolution
NSERHAN, C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.09.002 · Cited by 181
Medrikova, D., Jilkova, Z. M., Bardova, K., Janovska, P., Rossmeisl, M., & Kopecky, J. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.87 · Cited by 178 · cited 1×
“The distribution of adiponectin multimeric complexes in plasma was determined by Western blotting [61].”
MethodSelf-citationAntiobesity Effect of Eicosapentaenoic Acid in High-Fat/High-Sucrose Diet–Induced Obesity
Sato, A., Kawano, H., Notsu, T., Ohta, M., Nakakuki, M., Mizuguchi, K., Itoh, M., Suganami, T., & Ogawa, Y. (2010) · Diabetes · doi:10.2337/db09-1554 · Cited by 162 · cited 1×
“Moreover, conflicting data exist regarding the potential role of dietary macronutrient composition in the anti-obesity effects of LC n-3 PUFA [56,57].”
BackgroundJourdan, T., Djaouti, L., Demizieux, L., Gresti, J., Vergès, B., & Degrace, P. (2010) · Diabetes · doi:10.2337/db09-1482 · Cited by 161
Balvers, M. G. J., Verhoeckx, K. C. M., Plastina, P., Wortelboer, H. M., Meijerink, J., & Witkamp, R. F. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.06.006 · Cited by 158
Self-citationKunešová, M., Braunerová, R., Hlavatý, P., Tvrzická, E., Staňková, B., Škrha, J., Hilgertová, J., Hill, M., Kopecký, J., Wagenknecht, M., et al. (2006) · Physiological Research · doi:10.33549/physiolres.930770 · Cited by 152 · cited 1×
“However, in spite of the fact that LC n-3 PUFA could help to reduce obesity in humans [16,17] and prevent insulin resistance in rodents [8,18], they do not reverse insulin resistance in diabetic patients [19].”
BackgroundTandy, S., Chung, R. W. S., Wat, E., Kamili, A., Berge, K., Griinari, M., & Cohn, J. S. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf9016042 · Cited by 145 · cited 4×
“In line with previous data on krill oil [11,25,26,35], our results support the notion that the endocannabinoid system is involved in the mechanism of action of LC n-3 PUFA.”
BackgroundResultInfluentialKuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., Kazdova, L., Ogston, N., Baranowski, M., Gorski, J., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1305-z · Cited by 142 · cited 5×
“However, in spite of the fact that LC n-3 PUFA could help to reduce obesity in humans [16,17] and prevent insulin resistance in rodents [8,18], they do not reverse insulin resistance in diabetic patients [19].”
BackgroundMethodInfluentialSelf-citationLankinen, M., Schwab, U., Erkkilä, A., Seppänen-Laakso, T., Hannila, M.-L., Mussalo, H., Lehto, S., Uusitupa, M., Gylling, H., & Orešič, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005258 · Cited by 141 · cited 2×
“These data are consistent with the notion that cell membrane phospholipids represent an important reservoir of DHA and EPA and their processing into lipid signalling molecules [9,20,22], and they suggest that the difference in the effectiveness of the treatments is largely explained by differential accumulation of DHA…”
BackgroundResultPiscitelli, F., Carta, G., Bisogno, T., Murru, E., Cordeddu, L., Berge, K., Tandy, S., Cohn, J. S., Griinari, M., Banni, S., et al. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-51 · Cited by 141 · cited 6×
“Endocannabinoids in Dietary Obese Mice Reflecting (i) the pronounced differential effects of cHF+v3TGand cHF+v3PL-treatment on the liver and WAT of mice in the reversal study, and (ii) the association of the beneficial effects of LC n-3 PUFA administered as phospholipids with the modulation of endocannabinoid system i…”
BackgroundResultInfluentialIntestinal absorption of polyenephosphatidylcholine in man
Zierenberg, O., & Grundy, S. M. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38050-0 · Cited by 140
Kopecky, J., Rossmeisl, M., Flachs, P., Kuda, O., Brauner, P., Jilkova, Z., Stankova, B., Tvrzicka, E., & Bryhn, M. (2009) · Proceedings of the Nutrition Society · doi:10.1017/s0029665109990231 · Cited by 137
Self-citationMarine lipid‐based liposomes increase in vivo FA bioavailability
Cansell, M., Nacka, F., & Combe, N. (2003) · Lipids · doi:10.1007/s11745-003-1341-0 · Cited by 133
Flachs, P., Rühl, R., Hensler, M., Janovská, P., Zouhar, P., Kůs, V., Jílková, Z. M., Papp, E., Kuda, O., Svobodová, M., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2233-2 · Cited by 118 · cited 3×
“These data are consistent with the notion that cell membrane phospholipids represent an important reservoir of DHA and EPA and their processing into lipid signalling molecules [9,20,22], and they suggest that the difference in the effectiveness of the treatments is largely explained by differential accumulation of DHA…”
BackgroundResultSelf-citationKromhout, D., Geleijnse, J. M., de Goede, J., Oude Griep, L. M., Mulder, B. J. M., de Boer, M.-J., Deckers, J. W., Boersma, E., Zock, P. L., & Giltay, E. J. (2011) · Diabetes Care · doi:10.2337/dc11-0896 · Cited by 116
Rustan, A. C., Christiansen, E. N., & Drevon, C. A. (1992) · Biochemical Journal · doi:10.1042/bj2830333 · Cited by 115 · cited 1×
“In this respect, dietary intake of marine fish oils, namely long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) such as docosahexaenoic acid (DHA; 22:6n-3) and eicosapentaenoic acid (EPA; 20:5n-3), have been shown to exert profound hypolipidemic effects [2,3], reducing systemic inflammation [4,5] as well as low-g…”
BackgroundAnalysis of fatty acids in plasma lipoproteins by gas chromatography–flame ionization detection
TVRZICKÁ, E., Vecka, M., Staňková, B., & Žák, A. (2002) · Analytica Chimica Acta · doi:10.1016/s0003-2670(02)00396-3 · Cited by 110 · cited 2×
“In order to analyse the bioavailability of dietary DHA and EPA, the fatty acid composition of plasma lipids was evaluated by gas chromatography [36] in mice treated for two weeks with cHF+v3TG and cHF+v3PL diets at different levels of supplementation with the respective LC n-3 PUFA concentrate (Fig.”
MethodAmate, L., Gil, Á., & Ramírez, M. (2001) · Journal of Nutrition · doi:10.1093/jn/131.4.1250 · Cited by 96
Meijerink, J., Plastina, P., Vincken, J.-P., Poland, M., Attya, M., Balvers, M., Gruppen, H., Gabriele, B., & Witkamp, R. F. (2011) · British Journal of Nutrition · doi:10.1017/s0007114510005635 · Cited by 90 · cited 1×
“The pathophysiological role of the endocannabinoid system in the development of adipose tissue inflammation [47] or hepatic steatosis [48,49] is well described, and anti-inflammatory effects of adipocyte-derived EPEA or DHEA have recently been suggested [50,51].”
BackgroundSelf-citationJelenik, T., Rossmeisl, M., Kuda, O., Jilkova, Z. M., Medrikova, D., Kus, V., Hensler, M., Janovska, P., Miksik, I., Baranowski, M., et al. (2010) · Diabetes · doi:10.2337/db09-1716 · Cited by 88
Self-citationBanni, S., & Di Marzo, V. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900516 · Cited by 83 · cited 4×
“Levels of 2-AG in WAT were more efficiently reduced by LC n-3 PUFA administered as phospholipids, which was paralleled by decreased levels of AA in the diacylglycerol fraction, attesting to the latter’s precursor role in 2-AG synthesis [23].”
BackgroundInfluentialPacetti, D., Boselli, E., Hulan, H. W., & Frega, N. G. (2005) · Journal of Chromatography A · doi:10.1016/j.chroma.2005.08.016 · Cited by 77 · cited 1×
“It is likely that these phospholipid species are enriched with DHA, since it has previously been shown that, in egg phospholipids from hens fed on seal blubber oil [43,44], there is a preferential incorporation of DHA into the PE, PI, and PC fraction [43], especially in the sn-2 position of the phospholipid molecule […”
BackgroundPrevention and Reversal of Obesity and Glucose Intolerance in Mice by DHA Derivatives
Rossmeisl, M., Jelenik, T., Jilkova, Z., Slamova, K., Kus, V., Hensler, M., Medrikova, D., Povysil, C., Flachs, P., Mohamed‐Ali, V., et al. (2009) · Obesity · doi:10.1038/oby.2008.602 · Cited by 66
Self-citationLambert, D. M., & Muccioli, G. G. (2007) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e3282f00061 · Cited by 61
Kůs, V., Flachs, P., Kuda, O., Bardová, K., Janovská, P., Svobodová, M., Jílková, Z. M., Rossmeisl, M., Wang‐Sattler, R., Yu, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027126 · Cited by 56 · cited 2×
“With regard to treatment strategies for obesity-associated disorders, combined treatment using LC n-3 PUFA as triglycerides and pharmaceuticals like thiazolidinediones has been shown to be very effective [8,58].”
BackgroundSelf-citationCannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
Butler, H. L., & Korbonits, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0511 · Cited by 54 · cited 1×
“Selective blocking of the peripheral endocannabinoid system might nevertheless represent an effective and safe therapy [24,59].”
BackgroundSchuchardt, J. P., Neubronner, J., Kressel, G., Merkel, M., von Schacky, C., & Hahn, A. (2011) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2011.07.006 · Cited by 54 · cited 1×
“[60].”
TOF‐SIMS Analysis of Lipid Accumulation in the Skeletal Muscle of ob/ob Mice
Magnusson, Y. K., Friberg, P., Sjövall, P., Malm, J., & Chen, Y. (2008) · Obesity · doi:10.1038/oby.2008.424 · Cited by 50 · cited 2×
“The above results prompted us to increase the resolution of the analysis by performing time-of-flight secondary ion mass spectrometry (TOF-SIMS; [37,38]) on the liver, WAT and skeletal muscle of animals fed on cHF+v3TG and cHF+v3PL diets (matched for the DHA/EPA content; 30 g per kg diet).”
MethodSelf-citationRampone, A. J., & Long, L. R. (1977) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(77)90100-x · Cited by 48 · cited 1×
“This in turn is well absorbed and may augment LC n-3 PUFA delivery [40].”
BackgroundHigh-glycemic index carbohydrates abrogate the antiobesity effect of fish oil in mice
Hao, Q., Lillefosse, H. H., Fjære, E., Myrmel, L. S., Midtbø, L. K., Jarlsby, R. H., Ma, T., Jia, B., Petersen, R. K., Sonne, S. B., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00524.2011 · Cited by 40 · cited 1×
“Moreover, conflicting data exist regarding the potential role of dietary macronutrient composition in the anti-obesity effects of LC n-3 PUFA [56,57].”
BackgroundTOF-SIMS analysis of adipose tissue from patients with chronic kidney disease
Sjövall, P., Johansson, B. A., Belazi, D., Stenvinkel, P., Lindholm, B., Lausmaa, J., & Schalling, M. (2008) · Applied Surface Science · doi:10.1016/j.apsusc.2008.05.011 · Cited by 31
Self-citationVaitheesvaran, B., Yang, L., Hartil, K., Glaser, S. T., Yazulla, S., Bruce, J. E., & Kurland, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033717 · Cited by 29 · cited 1×
“The inhibition of the endocannabinoid system activity leads to beneficial metabolic effects, reflecting multiple mechanisms of endocannabinoid action mediated by their specific receptors as well as by PPAR-a (reviewed in [23,27]).”
BackgroundMiranville, A., Herling, A. W., Biemer‐Daub, G., & Voss, M. D. (2010) · Obesity · doi:10.1038/oby.2010.81 · Cited by 27 · cited 1×
“The pathophysiological role of the endocannabinoid system in the development of adipose tissue inflammation [47] or hepatic steatosis [48,49] is well described, and anti-inflammatory effects of adipocyte-derived EPEA or DHEA have recently been suggested [50,51].”
BackgroundPacetti, D., Hulan, H. W., Schreiner, M., Boselli, E., & Frega, N. G. (2005) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.2174 · Cited by 25
Cansell, M., Battin, A., Degrace, P., Gresti, J., Clouet, P., & Combe, N. (2009) · Lipids · doi:10.1007/s11745-008-3279-x · Cited by 19 · cited 1×
“In line with previous studies [30–34], our results document better bioavailability of both DHA and EPA when supplemented as dietary phospholipids and this effect can largely be attributed to a marked improvement in EPA bioavailability (see also ref.”
Result
Cited by
The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders
Silvestri, C., & Di Marzo, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.001 · Cited by 543
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“Moreover, Rossmeisl et al. (2012) suggested a possible role for DHEA in modulating inflammation in adipocytes.”
BackgroundHealth benefits of dietary marine DHA/EPA-enriched glycerophospholipids
Zhang, T.-T., Xu, J., Wang, Y.-M., & Xue, C.-H. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.100997 · Cited by 339
Marine Omega-3 Phospholipids: Metabolism and Biological Activities
Burri, L., Hoem, N., Banni, S., & Berge, K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131115401 · Cited by 257
Ahmmed, M. K., Ahmmed, F., Tian, H. (., Carne, A., & Bekhit, A. E. (2020) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12510 · Cited by 241
Metadata
- Authors
- Rossmeisl, M., Macek Jilkova, Z., Kuda, O., Jelenik, T., Medrikova, D., Stankova, B., Kristinsson, B., Haraldsson, G. G., Svensen, H., Stoknes, I., Sjövall, P., Magnusson, Y., Balvers, M. G. J., Verhoeckx, K. C. M., Tvrzicka, E., Bryhn, M., & Kopecky, J.
- Affiliations
- Czech Academy of Sciences (CZ)
- University of Iceland (IS)
- RISE Research Institutes of Sweden (SE)
- Sahlgrenska University Hospital (SE)
- Netherlands Organisation for Applied Scientific Research (NL)
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-06-11
- Volume
- 7
- Issue
- 6
- Pages
- e38834
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3372498
- OpenAlex
- W2038831823
- Cited by
- 230
- References
- 62
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 6 · 2023: 15 · 2022: 7 · 2021: 21 · 2020: 23 · 2019: 24 · 2018: 20 · 2017: 24 · 2016: 22 · 2015: 19 · 2014: 17 · 2013: 19 · 2012: 2
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TNO Repository (submittedVersion)
- ASEP (submittedVersion, public-domain)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Socio-Environmental Systems Modeling (submittedVersion)
- Repository hosted by TU Delft Library (TU Delft) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Grantová Agentura České Republiky (GAP301/10/1420)
- VINNOVA
- Ministerstvo Zdravotnictví Ceské Republiky
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- omega-3 fatty acids, docosahexaenoic acid, eicosapentaenoic acid, phospholipids, triglycerides, high-fat diet, obesity, endocannabinoids, 2-arachidonoylglycerol, hepatic steatosis, adipose tissue inflammation, adipocyte hypertrophy, insulin, impaired glucose tolerance, fatty acid bioavailability, marine fish oil
- MeSH terms
- Analysis of Variance, Animals, Biological Availability, Body Weight, Docosahexaenoic Acids, Immunohistochemistry, Liver, Male, Mice, Inbred C57BL, Microscopy, Obesity, Phospholipids, Triglycerides, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Muscle, Skeletal, Mice, Adipose Tissue, White, Metabolomics, Diet, High-Fat, Real-Time Polymerase Chain Reaction, Cannabinoid Receptor Modulators, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.